Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Nerve Tissue

ClinicalTrials.gov lists 8,900 trials for Neoplasms, Nerve Tissue or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 586.

MeSH D009380 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2,176 Phase 1/2 Phase 1/2 984 Phase 2 Phase 2 2,463 Phase 2/3 Phase 2/3 67 Phase 3 Phase 3 457 Phase 4 Phase 4 81 Not applicable Not applicable 1,097 Observational Observational 1,498 Phase 1 Phase 1 2,176 Phase 1/2 Phase 1/2 984 Phase 2 Phase 2 2,463 Phase 2/3 Phase 2/3 67 Phase 3 Phase 3 457 Phase 4 Phase 4 81 Not applicable Not applicable 1,097 Observational Observational 1,498

Trials per phase (log scale)

1 more section with rows

22 of the 8,900 trials are tagged with Neoplasms, Nerve Tissue itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasms, Nerve Tissue report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Nerve Tissue trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 33 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 473

1990: 6 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 2 1) 1991: 8 trials (Observational 3, Not applicable 1, Phase 2 2, Phase 1 2) 1992: 10 trials (Observational 2, Not applicable 3, Phase 3 3, Phase 2 2) 1993: 8 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 1994: 15 trials (Observational 1, Phase 3 3, Phase 2 7, Phase 1 4) 1995: 30 trials (Observational 5, Phase 3 5, Phase 2 12, Phase 1/2 2, Phase 1 6) 1996: 46 trials (Observational 4, Not applicable 1, Phase 3 5, Phase 2 23, Phase 1/2 1, Phase 1 12) 1997: 53 trials (Observational 6, Not applicable 1, Phase 3 4, Phase 2 21, Phase 1/2 7, Phase 1 14) 1998: 82 trials (Observational 6, Not applicable 3, Phase 3 6, Phase 2/3 2, Phase 2 43, Phase 1/2 6, Phase 1 16) 1999: 103 trials (Observational 9, Phase 3 12, Phase 2 52, Phase 1/2 6, Phase 1 24) 2000: 108 trials (Observational 12, Not applicable 6, Phase 3 10, Phase 2 30, Phase 1/2 21, Phase 1 29) 2001: 117 trials (Observational 8, Not applicable 4, Phase 4 1, Phase 3 12, Phase 2 40, Phase 1/2 16, Phase 1 36) 2002: 121 trials (Observational 7, Not applicable 7, Phase 3 12, Phase 2 43, Phase 1/2 20, Phase 1 32) 2003: 126 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 59, Phase 1/2 12, Phase 1 20) 2004: 174 trials (Observational 22, Not applicable 14, Phase 4 1, Phase 3 16, Phase 2/3 1, Phase 2 63, Phase 1/2 17, Phase 1 40) 2005: 222 trials (Observational 20, Not applicable 15, Phase 3 16, Phase 2/3 2, Phase 2 86, Phase 1/2 23, Phase 1 60) 2006: 231 trials (Observational 30, Not applicable 12, Phase 4 2, Phase 3 17, Phase 2/3 3, Phase 2 90, Phase 1/2 26, Phase 1 51) 2007: 230 trials (Observational 30, Not applicable 11, Phase 4 2, Phase 3 17, Phase 2/3 2, Phase 2 93, Phase 1/2 22, Phase 1 53) 2008: 263 trials (Observational 58, Not applicable 16, Phase 4 2, Phase 3 15, Phase 2 95, Phase 1/2 17, Phase 1 60) 2009: 275 trials (Other 1, Observational 35, Not applicable 21, Phase 4 1, Phase 3 16, Phase 2/3 2, Phase 2 92, Phase 1/2 33, Phase 1 74) 2010: 288 trials (Observational 36, Not applicable 16, Phase 4 1, Phase 3 14, Phase 2 104, Phase 1/2 39, Phase 1 78) 2011: 289 trials (Observational 43, Not applicable 26, Phase 4 3, Phase 3 13, Phase 2/3 6, Phase 2 91, Phase 1/2 27, Phase 1 80) 2012: 276 trials (Observational 44, Not applicable 35, Phase 4 5, Phase 3 13, Phase 2/3 1, Phase 2 76, Phase 1/2 33, Phase 1 69) 2013: 324 trials (Observational 51, Not applicable 42, Phase 4 6, Phase 3 16, Phase 2 93, Phase 1/2 26, Phase 1 90) 2014: 335 trials (Observational 51, Not applicable 43, Phase 4 3, Phase 3 12, Phase 2/3 5, Phase 2 95, Phase 1/2 37, Phase 1 89) 2015: 378 trials (Other 1, Observational 59, Not applicable 50, Phase 4 8, Phase 3 18, Phase 2/3 3, Phase 2 98, Phase 1/2 49, Phase 1 92) 2016: 375 trials (Observational 74, Not applicable 41, Phase 4 3, Phase 3 12, Phase 2/3 2, Phase 2 87, Phase 1/2 43, Phase 1 113) 2017: 409 trials (Observational 71, Not applicable 58, Phase 4 3, Phase 3 16, Phase 2/3 3, Phase 2 121, Phase 1/2 46, Phase 1 91) 2018: 415 trials (Observational 79, Not applicable 62, Phase 4 4, Phase 3 18, Phase 2/3 8, Phase 2 78, Phase 1/2 55, Phase 1 111) 2019: 404 trials (Observational 84, Not applicable 64, Phase 4 4, Phase 3 9, Phase 2/3 3, Phase 2 102, Phase 1/2 44, Phase 1 94) 2020: 417 trials (Observational 77, Not applicable 63, Phase 4 2, Phase 3 16, Phase 2/3 3, Phase 2 97, Phase 1/2 50, Phase 1 109) 2021: 473 trials (Observational 93, Not applicable 76, Phase 4 3, Phase 3 14, Phase 2/3 3, Phase 2 115, Phase 1/2 56, Phase 1 113) 2022: 469 trials (Observational 101, Not applicable 82, Phase 4 5, Phase 3 21, Phase 2/3 1, Phase 2 91, Phase 1/2 48, Phase 1 120) 2023: 407 trials (Observational 95, Not applicable 68, Phase 4 4, Phase 3 21, Phase 2/3 4, Phase 2 74, Phase 1/2 50, Phase 1 91) 2024: 416 trials (Observational 111, Not applicable 74, Phase 4 4, Phase 3 14, Phase 2/3 4, Phase 2 83, Phase 1/2 42, Phase 1 84) 2025: 432 trials (Observational 88, Not applicable 77, Phase 4 5, Phase 3 19, Phase 2/3 5, Phase 2 80, Phase 1/2 49, Phase 1 109)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 404
2025 432
2024 416
2023 407
2022 469
2021 473
2020 417
2019 404
2018 415
2017 409

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 440 trials starting in 2026 and about 440 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,086 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 5,276 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Nerve Tissue trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2,176
Phase 1/2 984
Phase 2 2,463
Phase 2/3 67
Phase 3 457
Phase 4 81
Not applicable 1,097
Observational 1,498
Expanded access 77

How many Neoplasms, Nerve Tissue trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 322
Recruiting 1,316
Enrolling by invitation 48
Active, not recruiting 693
Available 21

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Nerve Tissue trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 586
Children's Oncology Group 107
Novartis Pharmaceuticals 106
Bristol-Myers Squibb 93
European Organisation for Research and Treatment of Cancer - EORTC 66

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Neoplasms, Nerve Tissue? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 334
NIVOLUMAB 303
Cytoxan 289
IPILIMUMAB 258
Irinotecan 96

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SOC: Temozolomide 566
Radiation Therapy 265
Bevacizumab 1 219
or carboplatin 166
Etoposid 139

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Nerve Tissue trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malignant neoplasm progression 2,241 77
Pyrexia 1,966 273
Pneumonia 1,741 292
Fatigue 1,573 363
Vomiting 1,560 482

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Nerve Tissue? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Intradural spinal tumors: current classification and MRI features. Neuroradiology 2008 Yes
Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Annals of surgical oncology 2000 Yes
Rehabilitation of the cancer patient. The Medical clinics of North America 1969 No

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages